Minapharm, based in Egypt, is recognized as Africa’s only integrated biopharmaceutical company.

With over 25 years of experience in cellular and bioprocess engineering, the company is a key player in the pharmaceutical sectors of both Egypt and the broader Middle East.

Its business model combines European research and development with local manufacturing, which has expanded access to advanced medical treatments in underserved regions.

The collaboration aims to increase access to affordable biologic medicines for populations that have limited options and boost regional pharmaceutical exports.

Dr. Wafik Bardissi, Chairman and CEO of Minapharm, emphasized the importance of the deal, saying it reflects the company’s growing impact in biotherapeutics, cell and gene therapy, and platform technologies.

He welcomed Admaius not just as an investor, but as a strategic partner sharing Minapharm’s long-term goals.

Marlon Chigwende, Managing Partner at Admaius, called the investment a “landmark transaction.”

He praised the founding families and partners, describing Minapharm as a rare example of a business with the scale, innovation, and mission to combat critical health challenges like cancer.

Ahmed Rady, Managing Director at Admaius, highlighted the strength of the Minapharm team and its presence across Cairo and Berlin. He said the partnership would help scale a standout African company with advanced capabilities in science and manufacturing.

Dr. Shaheer Bardissi, Co-CEO of Minapharm, said the collaboration will help speed up the company’s plans to make cutting-edge treatments more affordable.